| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC4135 | Phomoxanthone A | Natural anti-tumor agent, showing strong apoptotic anticancer effects against platinum-resistant solid cancers |
|
| DCC4136 | Phosphatidylinositol | Potent antagonist of (H1N1)pdm09 infection, markedly suppressing cytopathic effects and attenuating viral gene expression in (H1N1)pdm09-infected MDCK cells |
|
| DCC4137 | phospho-sulindac | Sulindac derivative with promising anticancer activities |
|
| DCC4138 | Phosphotyrosine | Inducer of platelet aggregation, playing a role in cellular signal transduction and possibly in cell growth control and carcinogenesis |
|
| DCC4139 | Photac-i-3 | Novel photoswitchable BET bromodomain Degrader (PHOTAC) |
|
| DCC4140 | Photoazolol-1 | Novel potent photoswitchable antagonist for a precise spatiotemporal control of β2-adrenoceptors |
|
| DCC4141 | Photogbi1 | Novel photocontrol inhibitor of the voltage-gated proton channel Hv1 |
|
| DCC4142 | Photo-lenalidomide-acid | Functionalized photoswitchable cereblon ligand for Degraders |
|
| DCC4143 | Photos1p | Novel photoswitchable sphingolipid probe, reversibly controlled S1P3-dependent pain hypersensitivity in mice and uniquely suited for the study of S1P biology in cultured cells and in vivo |
|
| DCC4144 | Photosensitizer Pz I | Novel porphyrazine-based photodynamic anti-cancer agent, inducing immunogenic cell death |
|
| DCC4145 | Photosensitizer Pz Iii | Novel porphyrazine-based photodynamic anti-cancer agent, inducing immunogenic cell death |
|
| DCC4146 | Photosph | Novel photoswitchable sphingolipid probe |
|
| DCC4147 | Phototrexate | Novel photoswitchable inhibitor of human dihydrofolate reductase |
|
| DCC4148 | Phyllospadine | Natural flavonoidal alkaloid from the sea-grass Phyllosphadix iwatensis |
|
| DCC4149 | Physapubenolide | Natural cytotoxic withanolide antitumor agent, inducing apoptosis by decreasing mitochondrial membrane potential and elevating the Bax/Bcl-2 protein expression ratio |
|
| DCC4150 | Physodic Acid | Natural inhibitor of Wnt signaling, modulating β-catenin-dependent transcription |
|
| DCC4151 | Pi-090 | Platelet aggregation inhibitor |
|
| DCC4152 | Pi-091 | Platelet aggregation inhibitor |
|
| DCC4153 | Pi-2620 | Novel Tau ligand, displaying high Tau binding, low MAO-A binding, high brain uptake, and fast and complete brain washout |
|
| DCC4154 | Pi3k/akt/mtor-in-6be | Novel inhibitor of the PI3K/Akt/mTOR signaling pathways, activating P53 and inducing apoptosis |
|
| DCC4155 | Pi3k/akt-in-c89 | Novel Inhibitor of the PI3K-Akt Pathway, Inducing Autophagy of Female Germline Stem Cells |
|
| DCC4156 | Pi3kd/v-in-01 | Highly potent ATP-competitive PI3Kdelta/Vps34 dual inhibitor |
|
| DCC4157 | Pi3ki1 | Novel potent PI3K inhibitor with a modified omipalisib structure |
|
| DCC4158 | Pi3k-in-s1 | Novel PI3K inhibitor, synergizing with sorafenib in non-small cell lung cancer cells involving the Akt-S6 signaling. |
|
| DCC4159 | Piboserod Hydrochloride | Selective 5-HT4 receptor antagonist |
|
| DCC4160 | Picrasidine N | Novel Subtype-Selective PPARbeta/delta Agonist |
|
| DCC4161 | Picumeterol | Potent and selective beta2-adrenoceptor agonist |
|
| DCC4162 | Pikamilone Sodium | Prodrug of GABA, used for treatment of neurogenic bladder in spinal and benign prostatic hyperplasia |
|
| DCC4163 | Pik-c98 | Novel PI3K inhibitor, displaying potent preclinical activity against multiple myeloma |
|
| DCC4164 | Piloquinone | Natural activator of cryptic biosynthetic gene clusters (BGC), also acting as a potent inhibitor of monoamine oxidase B |
|
